Melanotan II: Melanocortin Receptor Research, Melanogenesis & Sexual Function

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is Melanotan II?

Melanotan II (MT-II) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (α-MSH), a naturally occurring neuropeptide involved in the regulation of melanogenesis, appetite, and sexual function. Its amino acid sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, featuring a lactam bridge between the aspartic acid and lysine residues that confers the cyclic structure critical to its receptor binding profile and enzymatic stability.

Melanotan II was originally developed in the early 1990s at the University of Arizona by researchers investigating synthetic melanocortin analogs with improved potency and stability compared to native α-MSH. The native hormone, a 13-amino-acid linear peptide, is rapidly degraded by proteolytic enzymes in vivo, limiting its utility in research protocols. By truncating the sequence, introducing non-natural amino acids (norleucine at position 1 and D-phenylalanine at position 7), and cyclizing the peptide backbone, the Arizona team produced a compound with substantially enhanced receptor affinity and resistance to enzymatic degradation.

Unlike its parent hormone, which acts primarily through the melanocortin 1 receptor (MC1R), Melanotan II is classified as a non-selective melanocortin receptor agonist, meaning it activates multiple melanocortin receptor subtypes — MC1R, MC3R, MC4R, and MC5R — with varying degrees of potency. This broad receptor activity profile is responsible for the diverse range of biological effects observed in preclinical and early clinical research, from melanogenesis stimulation to modulation of sexual function and feeding behavior.

It is worth noting that PT-141 (bremelanotide), an FDA-approved therapeutic for certain indications, is a direct metabolite and structural derivative of Melanotan II. The development of PT-141 from MT-II represents one of the more notable examples of a research peptide leading to an approved pharmaceutical product, a lineage explored in greater detail later in this guide.

Mechanism of Action: Melanocortin Receptor Agonism

The melanocortin system comprises five G-protein-coupled receptors (MC1R through MC5R), their endogenous agonists (α-MSH, β-MSH, γ-MSH, and ACTH), and the endogenous antagonists agouti-related protein (AgRP) and agouti signaling protein (ASIP). Melanotan II interacts with this system as a non-selective agonist, and its observed effects in research can be understood through its activity at each receptor subtype.

MC1R — Melanogenesis Pathway

MC1R is expressed primarily on melanocytes in the skin and hair follicles. When activated by Melanotan II, MC1R initiates a signaling cascade involving cyclic adenosine monophosphate (cAMP) elevation and subsequent activation of protein kinase A (PKA). This leads to phosphorylation of the cAMP response element-binding protein (CREB), which upregulates transcription of microphthalmia-associated transcription factor (MITF) — the master regulator of melanogenesis. MITF, in turn, promotes expression of the enzymes tyrosinase, TRP-1, and TRP-2, which catalyze the conversion of tyrosine to melanin pigment within melanosomes.

In preclinical models, MT-II administration has been observed to shift melanin production from pheomelanin (yellow-red pigment associated with lower photoprotective capacity) toward eumelanin (brown-black pigment with greater UV-absorbing properties). This shift has been a central focus of photoprotection research, as eumelanin-dominant skin exhibits greater intrinsic resistance to ultraviolet radiation-induced DNA damage.

MC3R — Energy Homeostasis

MC3R is expressed in the hypothalamus, particularly in the arcuate nucleus, as well as in peripheral tissues including the gut and immune cells. Research has implicated MC3R in the regulation of energy homeostasis, nutrient partitioning, and feeding behavior. In MC3R knockout mouse models, animals develop increased adiposity and altered metabolic efficiency even without hyperphagia, suggesting a role in energy storage and utilization rather than appetite alone.

Melanotan II’s agonism at MC3R has been investigated in the context of body composition research, with preclinical data suggesting effects on fat deposition and metabolic rate that are distinct from the appetite-suppressive effects mediated by MC4R.

MC4R — Appetite and Sexual Function

MC4R is arguably the most intensively studied melanocortin receptor and represents a critical node in two distinct research domains relevant to Melanotan II. Expressed in the paraventricular nucleus and other hypothalamic regions, MC4R activation has been associated in research with two principal downstream effects:

• Appetite regulation — MC4R agonism in the hypothalamus has been observed to reduce food intake in animal models. This anorectic effect is part of the leptin-melanocortin pathway, where leptin signaling from adipose tissue activates POMC neurons, which release α-MSH to stimulate MC4R and suppress feeding. Melanotan II mimics this endogenous signaling.
• Sexual arousal and erectile function — MC4R activation in the medial preoptic area and paraventricular nucleus of the hypothalamus has been observed to promote pro-erectile signaling in preclinical models. This pathway, involving downstream oxytocin release and descending autonomic nervous system activation, was the basis for the development of PT-141 (bremelanotide) from Melanotan II. The MC4R-mediated sexual function pathway is centrally acting, distinguishing it mechanistically from peripherally acting agents studied for erectile research.

MC5R — Exocrine Function

MC5R is expressed in sebaceous glands, adrenal glands, and various exocrine tissues. Research into MC5R has focused primarily on its role in sebum production and exocrine gland regulation. MC5R knockout mice exhibit severely impaired sebaceous lipid production and defects in water repulsion of the fur. While MC5R activation is not a primary research focus of Melanotan II investigations, it contributes to the peptide’s broad melanocortin receptor activity profile and may be relevant to dermatological research contexts.

Research Applications

The non-selective melanocortin receptor activity of Melanotan II has generated research interest across several domains. The following areas represent the most extensively investigated applications in published literature.

Melanogenesis and UV Photoprotection Research

The earliest and most extensively studied application of Melanotan II involves its capacity to stimulate melanin production via MC1R activation. In preclinical models, MT-II administration has been associated with increased melanocyte activity, elevated tyrosinase expression, and measurable increases in skin melanin density without UV exposure. This UV-independent tanning effect has been of particular interest to photobiology researchers investigating strategies for enhancing intrinsic photoprotection.

A series of early clinical studies conducted at the University of Arizona examined subcutaneous MT-II administration in human subjects and documented dose-dependent increases in skin pigmentation as measured by reflectance spectrophotometry. These studies, while small in scale, provided the first human evidence that exogenous melanocortin agonism could induce melanogenesis without ultraviolet radiation exposure.

Research has also investigated whether MT-II-induced melanogenesis might reduce susceptibility to UV-induced DNA damage. Preclinical data has suggested that eumelanin-enriched skin demonstrates reduced cyclobutane pyrimidine dimer (CPD) formation following UV exposure — a key biomarker of photocarcinogenic DNA damage. However, the translational implications of these findings remain under investigation, and no clinical studies have established a photoprotective benefit in human populations.

Sexual Function Research

The observation that Melanotan II induced pro-erectile effects in early clinical tanning studies was, by the investigators’ own account, an unexpected finding that redirected a significant portion of subsequent research. This serendipitous discovery identified the MC4R-mediated central arousal pathway and led directly to the development of PT-141 (bremelanotide), which was engineered as a more selective MC4R agonist derived from MT-II’s metabolic breakdown products.

In preclinical models, MT-II administration has been associated with increased intracavernosal pressure in rodent erectile function assays, enhanced lordosis behavior in female rodent models, and elevated oxytocin release from hypothalamic nuclei — all consistent with centrally mediated pro-sexual effects. The mechanism is distinct from nitric oxide/cGMP-dependent pathways studied with PDE5 inhibitors, as MT-II acts through hypothalamic melanocortin signaling rather than peripheral vascular mechanisms.

The clinical development of this pathway ultimately led to the FDA approval of bremelanotide (PT-141) in 2019 for hypoactive sexual desire disorder in premenopausal women, representing the most significant clinical translation of Melanotan II research to date. For a detailed examination of PT-141’s mechanism and clinical data, see our PT-141 Research Guide.

Appetite and Energy Homeostasis Research

Melanotan II’s agonism at MC3R and MC4R positions it within the central melanocortin appetite regulation pathway. In rodent models, intracerebroventricular (ICV) and peripheral administration of MT-II has been associated with dose-dependent reductions in food intake and body weight. These effects have been observed in both lean and diet-induced obese animal models, with MC4R knockout animals showing attenuated or absent anorectic responses — confirming MC4R as the primary mediator of MT-II’s appetite-suppressive effects.

Research has also examined the interaction between MT-II and the opposing orexigenic system mediated by agouti-related protein (AgRP) at MC3R and MC4R. In experimental paradigms, MT-II has been shown to override AgRP-induced hyperphagia, suggesting potent agonist activity that competes effectively with endogenous antagonist signaling at these receptors.

While these findings have contributed substantially to the understanding of central appetite regulation, it is important to note that no human clinical trials have investigated Melanotan II specifically for appetite or body composition endpoints. The appetite research has remained primarily in the preclinical domain.

Melanocortin System and Inflammation Research

The melanocortin system has been increasingly recognized as a modulator of inflammatory processes, and Melanotan II has been investigated in this context alongside other melanocortin peptides, including KPV, a tripeptide fragment of α-MSH with anti-inflammatory research applications. In preclinical models of colitis, arthritis, and ischemia-reperfusion injury, melanocortin agonism has been associated with reduced pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β) and attenuation of NF-κB signaling. While much of this anti-inflammatory research has focused on more selective melanocortin agonists and fragments, MT-II’s broad receptor activity profile has made it a useful pharmacological tool for probing melanocortin-mediated immune modulation in laboratory settings.

Dosing in Published Research

The following table summarizes dosing parameters reported in published preclinical and early clinical research involving Melanotan II. These values are provided for research reference only and do not constitute dosing recommendations.

Parameter	Published Research Values	Notes
Species studied	Mice, rats, humans (early clinical)	Majority of data from rodent models
Rodent doses (melanogenesis)	0.5–1.0 mg/kg subcutaneous	Dose-dependent pigmentation response
Rodent doses (feeding studies)	0.1–1.0 nmol ICV; 1–10 mg/kg peripheral	ICV more potent; MC4R-mediated
Early human studies (U of A)	0.010–0.025 mg/kg subcutaneous	Dose-dependent pigmentation observed
Administration routes studied	Subcutaneous, intracerebroventricular, intranasal	SC most common in clinical research
Molecular weight	1,024.18 Da	Cyclic heptapeptide
Solubility	Soluble in sterile water, bacteriostatic water	Store reconstituted at 2–8 °C

Important: Rodent doses cannot be directly extrapolated to other species using simple body weight scaling. Allometric scaling, interspecies pharmacokinetic differences, and route-of-administration variables all affect dose translation. No validated dosing protocol exists for Melanotan II outside of controlled research settings.

Reconstitution and Handling

Melanotan II is typically supplied as a lyophilized (freeze-dried) powder and requires reconstitution prior to use in research protocols. Proper handling is essential for maintaining peptide integrity and ensuring reproducible experimental results.

Reconstitution Protocol

• Solvent: Reconstitute with bacteriostatic water (0.9% benzyl alcohol) for multi-use applications, or sterile water for single-use protocols.
• Technique: Direct the solvent stream against the vial wall, allowing it to run down and contact the lyophilized cake gently. Do not inject directly onto the peptide powder, as forceful reconstitution can cause foaming and potential denaturation.
• Mixing: Allow the peptide to dissolve naturally over 1–2 minutes. If necessary, gently swirl the vial — do not vortex or shake vigorously, as mechanical agitation can disrupt the cyclic peptide structure.
• Visual inspection: The reconstituted solution should be clear and colorless. Discard any solution that appears cloudy, contains particulate matter, or shows discoloration.

Storage Conditions

Form	Storage Temperature	Recommended Stability
Lyophilized powder	-20 °C (freezer)	Up to 24 months
Reconstituted (bacteriostatic water)	2–8 °C (refrigerator)	Up to 4 weeks
Reconstituted (sterile water)	2–8 °C (refrigerator)	Use within 48 hours

• Protect from light — store in amber vials or wrap in foil.
• Avoid repeated freeze-thaw cycles, which can degrade the cyclic structure.
• Aliquot reconstituted solution into single-use volumes where practical to minimize contamination and degradation.

Safety Profile Observed in Research

The safety data available for Melanotan II is derived from a combination of early-phase human studies, preclinical toxicology, and post-market surveillance of its derivative PT-141. It is important to emphasize that Melanotan II has not completed the standard Phase I through Phase III clinical trial program required for regulatory approval, and its safety profile in humans is therefore incompletely characterized.

Observations from Early Clinical Studies

The University of Arizona studies that first characterized MT-II’s melanogenic effects in human subjects also documented several commonly reported observations:

• Nausea — The most frequently reported effect in early clinical studies, appearing in a dose-dependent manner. Nausea was generally transient and tended to diminish with repeated exposures in the published protocols.
• Facial flushing — Transient vasodilation-related flushing was observed in some subjects, consistent with melanocortin receptor activation in vascular tissues.
• Fatigue and yawning — Reported in some subjects, potentially related to central melanocortin and oxytocin pathway activation.
• Appetite changes — Reduced appetite was noted in some study participants, consistent with the MC4R-mediated anorectic effects observed in preclinical models.
• Pigmented lesion changes — Some studies reported darkening of pre-existing nevi (moles) in subjects receiving MT-II. This observation has prompted recommendations in the literature for dermatological monitoring in any research protocol involving melanocortin agonists.

Theoretical and Preclinical Concerns

Several safety considerations have been discussed in published literature that warrant attention from researchers:

• Melanocyte activation and nevi — The stimulation of melanocyte proliferation and activity raises theoretical considerations regarding melanocytic lesions. While no causal association between MT-II and melanoma has been established in published research, the stimulation of melanogenesis — particularly in individuals with atypical mole syndrome or other risk factors — has been identified as an area requiring careful investigation. A number of case reports in dermatological literature have described changes in pigmented lesions temporally associated with MT-II use, though causality has not been established.
• Cardiovascular considerations — Melanocortin receptors are expressed in cardiovascular tissues, and MC4R activation has been associated with transient increases in blood pressure in some research contexts. The clinical significance of this observation remains under investigation.
• Non-selectivity — MT-II’s activity across multiple melanocortin receptor subtypes means that desired effects at one receptor (e.g., MC1R for melanogenesis) are necessarily accompanied by activity at others (MC3R, MC4R, MC5R), producing a broader range of physiological effects than a selective agonist would. This non-selectivity was, in fact, the motivation for developing more selective derivatives such as PT-141 (MC4R-preferring) for specific research applications.

Regulatory Status

Melanotan II has not been approved by the FDA, EMA, TGA, or any other regulatory authority for human therapeutic use. Multiple regulatory agencies, including the FDA and TGA (Therapeutic Goods Administration, Australia), have issued warnings regarding unregulated MT-II products. These warnings have focused on quality control concerns with products sold outside regulated pharmaceutical channels, the lack of completed clinical safety data, and the potential for harm from unmonitored use.

Melanotan II remains available for legitimate research purposes and is sold by research chemical suppliers as a research reagent. Researchers and institutions should verify the regulatory status in their specific jurisdiction.

Relationship to PT-141 (Bremelanotide)

The relationship between Melanotan II and PT-141 (bremelanotide) represents a notable case study in peptide drug development. PT-141 is a linear metabolite of Melanotan II, formed by the loss of the C-terminal amide group during in vivo metabolism. When researchers at the University of Arizona identified the pro-erectile effects of MT-II as being mediated primarily through MC4R, efforts were directed toward developing a derivative that retained MC4R activity while reducing the MC1R-mediated melanogenic effects.

Bremelanotide emerged from this work as an MC4R-preferring agonist that retained the sexual function-related activity of MT-II while exhibiting reduced melanogenic potency. Following a full clinical development program, bremelanotide (marketed as Vyleesi) received FDA approval in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women, making it the first melanocortin-based therapeutic to reach the market.

For researchers interested in the MC4R sexual function pathway specifically, our PT-141 Research Guide provides a comprehensive examination of bremelanotide’s mechanism, clinical trial data, and regulatory history.

Summary

Melanotan II occupies a distinctive position in peptide research as one of the first synthetic melanocortin analogs to demonstrate broad biological activity across multiple receptor subtypes. Its non-selective agonism at MC1R, MC3R, MC4R, and MC5R has generated a diverse preclinical research profile spanning melanogenesis, sexual function, appetite regulation, and inflammation — and its direct contribution to the development of FDA-approved bremelanotide (PT-141) represents a tangible translation from research peptide to approved therapeutic.

Key points for researchers:

• Melanotan II is a cyclic heptapeptide analog of α-MSH with non-selective melanocortin receptor agonist activity.
• MC1R activation drives melanogenesis and has been the focus of UV photoprotection research.
• MC4R activation mediates both appetite-suppressive and pro-sexual effects observed in preclinical and early clinical studies.
• PT-141 (bremelanotide) is a direct metabolite and derivative, developed to achieve more selective MC4R agonism.
• Human safety data remains limited to early-phase studies; Melanotan II has not completed a standard clinical development program.
• Regulatory agencies have not approved MT-II for any therapeutic indication.

The melanocortin system continues to be an active area of pharmacological research, and Melanotan II remains a widely used tool compound for investigating melanocortin receptor biology. Researchers working with MT-II should ensure compliance with all applicable institutional and regulatory guidelines.

---

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Böhm et al.	2024	Review	Benefits and risks of chronic MC1R activation	PMC11664455
King et al.	2007	Review	Melanocortin receptors and penile erection mechanisms	PMC2694735
Hadley et al.	2005	Review	Design of bioavailable melanotropin peptides	PMC5953761
Langan et al.	2021	Case Report	Melanotan injection causing priapism	PMC7930850
Hjuler et al.	2020	Case Report	Melanotan II renal infarction case review	PMC7148395
Tala et al.	2020	Research	Topical MTII suppresses melanoma via PTEN upregulation	PMC7013727
Haskell-Luevano et al.	2019	Research	Discovery of highly selective MC1R agonist pentapeptide	PMC6940745

Research Disclaimer

For laboratory and research use only. Not for human consumption.

This article is intended solely as a summary of published scientific research on Melanotan II. It does not constitute medical advice, treatment recommendations, or an endorsement of Melanotan II for any therapeutic purpose. Melanotan II has not been approved by the FDA or any regulatory agency for human use. The research discussed herein includes both preclinical (animal and cell culture) and limited early clinical data, and results from such studies may not generalize to broader human populations. Researchers should consult relevant institutional review boards and regulatory guidelines before designing studies involving this compound.

NorthPeptide supplies research-grade peptides for legitimate scientific investigation. All products are sold strictly for laboratory and research purposes. https://northpeptide.com/products/melanotan-ii